Sinotherapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	446.57	511.08	299.41	246.69	314.38
Other Revenue	-	0.54	0.46	0.87	1.09
Revenue	446.57	511.62	299.87	247.56	315.47
Revenue Growth (YoY)	-12.72%	70.61%	21.13%	-21.53%	-1.16%
Cost of Revenue	270.54	246.11	133.5	68.44	70.44
Gross Profit	176.03	265.51	166.37	179.12	245.03
Selling, General & Admin	47	55.25	43.93	43.9	45.71
Research & Development	74.94	84.92	74.01	76.02	103.63
Other Operating Expenses	-7.44	2.19	3.03	-0.63	0.77
Operating Expenses	114.5	146.02	122.07	120.91	149.94
Operating Income	61.52	119.48	44.3	58.21	95.1
Interest Expense	-	-0	-0.04	-0.21	-0.23
Interest & Investment Income	9.91	16.38	17.45	25.02	5.66
Currency Exchange Gain (Loss)	-	2.07	1.26	5.52	-4
Other Non Operating Income (Expenses)	-1.9	-0.07	-0.06	-0.05	0.43
EBT Excluding Unusual Items	69.53	137.86	62.91	88.48	96.95
Gain (Loss) on Sale of Investments	1.34	-	-	-	0.46
Gain (Loss) on Sale of Assets	-	-0.59	-0.11	0.12	-0.02
Asset Writedown	-17.54	-0.92	-1.62	-0.85	-0.1
Other Unusual Items	-	5.74	4.8	9.73	51.72
Pretax Income	53.34	142.08	65.99	97.48	149.01
Income Tax Expense	5.85	14.38	4.92	4.54	14.1
Net Income	47.48	127.7	61.07	92.93	134.92
Net Income to Common	47.48	127.7	61.07	92.93	134.92
Net Income Growth	-62.82%	109.09%	-34.28%	-31.12%	9.42%
Shares Outstanding (Basic)	432	456	470	422	409
Shares Outstanding (Diluted)	432	456	470	422	409
Shares Change (YoY)	-5.35%	-2.92%	11.22%	3.32%	0.21%
EPS (Basic)	0.11	0.28	0.13	0.22	0.33
EPS (Diluted)	0.11	0.28	0.13	0.22	0.33
EPS Growth	-60.71%	115.39%	-40.91%	-33.33%	10.00%
Free Cash Flow	53.77	35.3	-26	-103.15	129.77
Free Cash Flow Per Share	0.13	0.08	-0.06	-0.24	0.32
Dividend Per Share	-	0.062	0.041	0.062	-
Dividend Growth	-	51.22%	-33.87%	-	-
Gross Margin	39.42%	51.90%	55.48%	72.35%	77.67%
Operating Margin	13.78%	23.35%	14.77%	23.51%	30.14%
Profit Margin	10.63%	24.96%	20.37%	37.54%	42.77%
Free Cash Flow Margin	12.04%	6.90%	-8.67%	-41.67%	41.13%
EBITDA	93.35	137.79	67.38	83.75	121.21
EBITDA Margin	20.91%	26.93%	22.47%	33.83%	38.42%
D&A For EBITDA	31.83	18.3	23.08	25.55	26.12
EBIT	61.52	119.48	44.3	58.21	95.1
EBIT Margin	13.78%	23.35%	14.77%	23.51%	30.14%
Effective Tax Rate	10.97%	10.12%	7.45%	4.66%	9.46%
Revenue as Reported	-	511.62	299.87	247.56	315.47
Advertising Expenses	-	0.77	0.42	0.69	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.